<DOC>
	<DOCNO>NCT00548171</DOCNO>
	<brief_summary>The purpose study assess efficacy safety repeat dTpa booster adult 10 year previous booster vaccination dTpa previous clinical study . Only subject receive booster vaccination previous clinical study eligible participation study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 . No new recruitment perform booster phase ( see inclusion criterion )</brief_summary>
	<brief_title>Immunogenicity &amp; Reactogenicity Boostrix 10 Years After Previous Booster Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Subjects receive dTpa vaccine Td pa vaccine study 263855/002 . A male female subject , recruit 10 year ( +/ 9 month ) booster vaccination study 263855/002 . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion booster vaccination . Written inform consent obtain subject . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior booster vaccination , plan administration active study period Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Previous booster vaccination diphtheria , tetanus pertussis since last dose receive study 263855/002 History diphtheria , tetanus , pertussis disease . Any confirm suspected immunosuppressive immunodeficiency condition , base medical history physical examination History allergic disease reaction likely exacerbate component vaccine . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Occurrence follow adverse event previous administration DTP vaccine : hypersensitivity reaction component vaccine ; encephalopathy unknown aetiology occur within 7 day follow previous vaccination pertussiscontaining vaccine ; fever ≥ 40 °C ( axillary temperature ) within 48 hour vaccination due another identifiable cause ; collapse shocklike state within 48 hour vaccination ; convulsion without fever , occur within 3 day vaccination . Acute disease time enrolment . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>28 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>